<DOC>
	<DOCNO>NCT01018758</DOCNO>
	<brief_summary>This open-label , multicenter phase II study patient aggressive Non Hodgkin Lymphoma schedule receive moderately emetogenic polychemotherapy ( accord modify Hesketh classification antiemetic therapy ) .</brief_summary>
	<brief_title>Study With Palonosetron Alone Preventing Chemotherapy-induced Nausea Vomiting Untreated Patients With Aggressive Non Hodgkin 's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Male female , &gt; 18 year age ; Histologically cytologically confirm aggressive NHL ( stage accordance REAL Classification ) ; Patients candidate initial chemotherapy treatment ; ECOG performance status 01 ; Scheduled receive single intravenous dose least one moderately emetogenic agent ( accord modify Hesketh classification ) Day 1 ; Written inform consent ; Female childbearing potential must use reliable contraceptive measure ; Acceptable hepatic renal function ; Willing able complete patient diary . Highly emetogenic chemotherapy ( contain cisplatin , mechlorethamine , streptozotocin , cyclophosphamide &gt; 1500 mg/sqm ; carmustine ; dacarbazine ; hexamethylmelamine ; procarbazine ) , singleagent chemotherapy drug low/minimal emetogenic potential accord Hesketh classification ) ; Diagnosis Hodgkin 's Disease Leukemia ; Candidates HighDose Chemotherapy Bone Marrow/Peripheral Blood Stem Cells Transplantation ; Chemotherapy schedule consider administration emetogenic drug two consecutive day ; Have receive investigational drug within 30 day study entry ; Have receive drug potential antiemetic efficacy ( exception specific corticosteroid foreseen chemotherapy combination ) within 24 hour treatment initiation ) ; Prior treatment Palonosetron ; Have seizure disorder require anticonvulsant medication unless clinically stable free seizure activity ; Experienced ongoing vomit nausea organic etiology , screen phase ; Clinical evidence current impend bowel obstruction , peritonitis , infection , uremia , severe mucositis ; Clinically relevant electrolyte abnormality ; Have know hypersensitivity 5HT3 receptor antagonist ; Radiotherapy within 30 day chemotherapy administration , schedule receive radiotherapy within two week chemotherapy ; Female patient pregnant breast feeding ; Inability understand cooperate study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Quality life</keyword>
	<keyword>Chemotherapy toxicity</keyword>
	<keyword>aggressive Non Hodgkin 's Lymphomas treat moderately emetogenic chemotherapy</keyword>
</DOC>